(Q36850764)

16 August 2017

1 reference

title

Blood and marrow transplantation in elderly acute myeloid leukaemia patients - older certainly is not better (English)

1 reference

16 August 2017

1 reference

Kiss TL

1

1 reference

16 August 2017

Sabry W

series ordinal

2

1 reference

16 August 2017

Lazarus HM

series ordinal

3

1 reference

16 August 2017

Lipton JH

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

18 June 2007

1 reference

Bone Marrow Transplantation

16 August 2017

1 reference

16 August 2017

40

1 reference

16 August 2017

5

1 reference

16 August 2017

405-416

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705747

16 August 2017

0 references

cites work

Population-based age- and sex-specific incidence rates in the 4 main types of leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Cytogenetic findings in adult de novo acute myeloid leukaemia. A population‐based study of 303/337 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

The difficult problem of acute myeloid leukemia in the older adult

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Management of acute myeloid leukemia in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Acute myeloid leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Acute myeloblastic leukaemia in the elderly: biology, prognostic factors and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

The relationship of patient age to the pathobiology of the clonal myeloid diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

The challenge of acute myeloid leukemia in older patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Autologous stem cell transplantation for adult acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Risk factors for acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705747

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705747

1 reference

16 August 2017

1 reference